Browse the corpus

REFERENCES Adatia I, "Improving the Outcome of Childhood Pulmonary Arterial Hypertension: The Effect of Bosentan in the Setting of a Dedicated Pulmonary Hypertension Clinic," J Am Coll Cardiol , 2005, 46(4):705-6. [PubMed 16098439 ] Apostolopoulou SC, Manginas A, Cokkinos DV, et al, "Long-Term Oral Bosentan Treatment in Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease: A 2-Year Study," Heart , 2007, 93(3):350-4. [PubMed 16980516 ] Barst RJ, Ivy D, Dingemanse J, et al, "Pharmacokinetics, Safety, and Efficacy of Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension," Clin Pharmacol Ther , 2003, 73(4):372-82. [PubMed 12709727 ] Beghetti M, "Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension," Curr Vasc Pharmacol , 2009, 7(2):225-33. [PubMed 19356006 ] Beghetti M, "Current Treatment Options in Children With Pulmonary Arterial Hypertension and Experiences With Oral Bosentan," Eur J Clin Invest , 2006, 36(Suppl 3):16-24. [PubMed 16919006 ] Beghetti M, Haworth SG, Bonnet D, et al, "Pharmacokinetic and Clinical Profile of a Novel Formulation of Bosentan in Children With Pulmonary Arterial Hypertension: The FUTURE-1 Study," Br J Clin Pharmacol , 2009a, 68(6):948-55. [PubMed 20002090 ] Beghetti M, Hoeper MM, Kiely DG, et al, "Safety Experience With Bosentan in 146 Children 2-11 Years Old With Pulmonary Arterial Hypertension: Results From the European Postmarketing Surveillance Program," Pediatr Res , 2008, 64(2):200-4. [PubMed 18414142 ] Carter NJ and Keating GM, "Bosentan: In Pediatric Patients With Pulmonary Arterial Hypertension," Paediatr Drugs , 2010, 12(1):63-73. [PubMed 20034342 ] Gilbert N, Luther YC, Miera O, et al, "Initial Experience With Bosentan (Tracleer®) as Treatment for Pulmonary Arterial Hypertension (PAH) Due to Congenital Heart Disease in Infants and Young Children," Z Kardiol , 2005, 94(9):570-4. [PubMed 16142516 ] Goissen C, Ghyselen L, Tourneux P, et al, "Persistent Pulmonary Hypertension of the Newborn With Transposition of the Great Arteries: Successful Treatment With Bosentan," Eur J Pediatr , 2008, 167(4):437-40. [PubMed 17701214 ] Ivy DD, Doran A, Claussen L, et al, "Weaning and Discontinuation of Epoprostenol in Children With Idiopathic Pulmonary Arterial Hypertension Receiving Concomitant Bosentan," Am J Cardiol , 2004, 93(7):943-6. [PubMed 15050507 ]

Goissen C, Ghyselen L, Tourneux P, et al, "Persistent Pulmonary Hypertension of the Newborn With Transposition of the Great Arteries: Successful Treatment With Bosentan," Eur J Pediatr , 2008, 167(4):437-40. [PubMed 17701214 ] Ivy DD, Doran A, Claussen L, et al, "Weaning and Discontinuation of Epoprostenol in Children With Idiopathic Pulmonary Arterial Hypertension Receiving Concomitant Bosentan," Am J Cardiol , 2004, 93(7):943-6. [PubMed 15050507 ] Ivy DD, Rosenzweig EB, Lemarié JC, et al, "Long-Term Outcomes in Chidren With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings," Am J Cardiol , 2010, 106(9):1332-8. [PubMed 21029834 ] Lunze K, Gilbert N, Mebus S, et al, "First Experience With an Oral Combination Therapy Using Bosentan and Sildenafil for Pulmonary Arterial Hypertension," Eur J Clin Invest , 2006, 36 Suppl 3:32-8. [PubMed 16919008 ] Maiya S, Hislop AA, Flynn Y, et al, "Response to Bosentan in Children With Pulmonary Hypertension," Heart , 2006, 92(5):664-70. [PubMed 16216850 ] Nakwan N, Choksuchat D, Saksawad R, et al, "Successful Treatment of Persistent Pulmonary Hypertension of the Newborn With Bosentan," Acta Paediatr , 2009, 98(10):1683-5. [PubMed 19523174 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Rosenzweig EB, Ivy DD, Widlitz A, et al, "Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension," J Am Coll Cardiol , 2005, 46(4):697-704. [PubMed 16098438 ] Sitbon O, Beghetti M, Petit J, et al, "Bosentan for the Treatment of Pulmonary Arterial Hypertension Associated With Congenital Heart Defects," Eur J Clin Invest , 2006, 36(Suppl 3):25-31. [PubMed 16919007 ] Villanueva D. Medical Information Manager, Actelion, personal correspondence, March 2006. Topic 13087 Version 49.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]